Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- NEUP
- Price
- 4.06
- Stock movement up
- +0.01 (0.25%)
- Company name
- Neuphoria Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 21.83M
- Ent value
- 23.02M
- Price/Sales
- 2.35
- Price/Book
- 1.75
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 18.12%
- 1 year return (CAGR)
- -
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
NEUP does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | 0.28 |
| Price to FCF | 0.28 |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.35 |
| Price to Book | 1.75 |
| EV to Sales | 2.48 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 5.38M |
| EPS (TTM) | -168.45 |
| FCF per share (TTM) | 34.67 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 9.28M |
| Gross profit (TTM) | 8.69M |
| Operating income (TTM) | -1.13B |
| Net income (TTM) | -378.35M |
| EPS (TTM) | -168.45 |
| EPS (1y forward) | -3.85 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 93.63% |
| Operating margin (TTM) | -12166.05% |
| Profit margin (TTM) | -4076.08% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 13.65M |
| Net receivables | 1.76K |
| Total current assets | 13.95M |
| Goodwill | 8.67M |
| Intangible assets | 4.64M |
| Property, plant and equipment | 77.79K |
| Total assets | 27.34M |
| Accounts payable | 1.37M |
| Short/Current long term debt | 85.21K |
| Total current liabilities | 5.12M |
| Total liabilities | 14.83M |
| Shareholder's equity | 12.51M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 77.87M |
| Capital expenditures (TTM) | 6.00 |
| Free cash flow (TTM) | 77.87M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -3024.31% |
| Return on Assets | -1383.66% |
| Return on Invested Capital | -3003.85% |
| Cash Return on Invested Capital | 618.22% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.00 |
| Daily high | 4.09 |
| Daily low | 3.98 |
| Daily Volume | 11K |
| All-time high | 20.00 |
| 1y analyst estimate | 9.77 |
| Beta | - |
| EPS (TTM) | -168.45 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| NEUP | S&P500 | |
| Current price drop from All-time high | -79.70% | -1.82% |
| Highest price drop | -81.40% | -56.47% |
| Date of highest drop | 26 Dec 2025 | 9 Mar 2009 |
| Avg drop from high | -64.86% | -10.84% |
| Avg time to new high | 14 days | 12 days |
| Max time to new high | 92 days | 1805 days |
COMPANY DETAILS
Marketcap
21.83M
Marketcap category
Small-cap
Description
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.
Employees
7
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner